Literature DB >> 24289639

Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.

Si-Ying Chen1, Sa-Sa Hu, Qian Dong, Jiang-Xia Cai, Wei-Peng Zhang, Jin-Yao Sun, Tao-Tao Wang, Jiao Xie, Hai-Rong He, Jian-Feng Xing, Jun Lu, Ya-Lin Dong.   

Abstract

BACKGROUND: Breast cancer is a common malignant tumor which affects health of women and multidrug resistance (MDR) is one of the main factors leading to failure of chemotherapy. This study was conducted to establish paclitaxel-resistant breast cancer cell line and nude mice models to explore underlying mechanisms of MDR.
METHODS: The breast cancer drug-sensitive cell line MCF-7 (MCF-7/S) was exposed in stepwise escalating paclitaxel (TAX) to induce a resistant cell line MCF-7/TAX. Cell sensitivity to drugs and growth curves were measured by MTT assay. Changes of cell morphology and ultrastructure were examined by optical and electron microscopy. The cell cycle distribution was determined by flow cytometry. Furthermore, expression of proteins related to breast cancer occurrence and MDR was tested by immunocytochemistry. In Vivo, nude mice were injected with MCF-7/S and MCF-7/TAX cells and weights and tumor sizes were observed after paclitaxel treatment. In addition, proteins involved breast cancer and MDR were detected by immunohistochemistry.
RESULTS: Compared to MCF-7/S, MCF-7/TAX cells had a higher resistance to paclitaxel, cross-resistance and prolonged doubling time. Moreover, MCF-7/TAX showed obvious alterations of ultrastructure. Estrogen receptor (ER) expression was low in drug resistant cells and tumors while expression of human epidermal growth factor receptor 2 (HER2) and Ki-67 was up-regulated. P-glycoprotein (P-gp), lung resistance-related protein (LRP) and glutathione-S-transferase-π (GST-π) involved in the MDR phenotype of resistant cells and tumors were all overexpressed.
CONCLUSION: The underlying MDR mechanism of breast cancer may involve increased expression of P-gp, LRP and GST-π.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24289639     DOI: 10.7314/apjcp.2013.14.10.6135

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  18 in total

1.  Salvianolic acid A reverses the paclitaxel resistance and inhibits the migration and invasion abilities of human breast cancer cells by inactivating transgelin 2.

Authors:  Xiaowei Zheng; Siying Chen; Qianting Yang; Jiangxia Cai; Weipeng Zhang; Haisheng You; Jianfeng Xing; Yalin Dong
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 2.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.

Authors:  Mostafa Vaghari-Tabari; Parisa Hassanpour; Fatemeh Sadeghsoltani; Faezeh Malakoti; Forough Alemi; Durdi Qujeq; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-06-17       Impact factor: 8.702

3.  A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis.

Authors:  Imran Shair Mohammad; Wei He; Lifang Yin
Journal:  Pharm Res       Date:  2018-02-27       Impact factor: 4.200

Review 4.  Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.

Authors:  P S Thakur; A M Khan; S Talegaonkar; F J Ahmad; Z Iqbal
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-26       Impact factor: 4.553

5.  Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.

Authors:  Hajime Asada; Hirotaka Tomiyasu; Yuko Goto-Koshino; Yasuhito Fujino; Koichi Ohno; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2015-02-21       Impact factor: 1.267

6.  MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.

Authors:  Qingling Yang; Yangyang Wang; Xiaohui Lu; Zunlan Zhao; Lihua Zhu; Sulian Chen; Qiong Wu; Changjie Chen; Zhiwei Wang
Journal:  Oncotarget       Date:  2015-02-20

7.  Galectin-1 knockdown improves drug sensitivity of breast cancer by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathway.

Authors:  Fang Wang; Pengwei Lv; Yuanting Gu; Lin Li; Xin Ge; Guangcheng Guo
Journal:  Oncotarget       Date:  2017-04-11

8.  Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells.

Authors:  Q Yang; J Huang; Q Wu; Y Cai; L Zhu; X Lu; S Chen; C Chen; Z Wang
Journal:  Br J Cancer       Date:  2014-03-18       Impact factor: 7.640

9.  Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein.

Authors:  Shengpeng Wang; Lu Wang; Zhi Shi; Zhangfeng Zhong; Meiwan Chen; Yitao Wang
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

10.  CLDN6 promotes chemoresistance through GSTP1 in human breast cancer.

Authors:  Minlan Yang; Yanru Li; Xiangfeng Shen; Yang Ruan; Yan Lu; Xiangshu Jin; Peiye Song; Yantong Guo; Xiaoli Zhang; Huinan Qu; Yijia Shao; Chengshi Quan
Journal:  J Exp Clin Cancer Res       Date:  2017-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.